Characterizing the Mutational Landscape of Diffuse Large B-Cell Lymphoma in a Prospective Cohort of Mexican Patients
Abstract
:1. Introduction
2. Results
2.1. Patient Characteristics
2.2. Mutational Landscape of Mexican Patients with DLCBL
2.3. Correlations between Clinical Features and Mutational Profiles
2.4. Survival Analysis
2.5. Impact of Clinical and Molecular Features on Survival
3. Discussion
4. Material and Methods
4.1. Study Design
4.2. Study Variables
4.3. Tissue Sample Preparation
4.4. Bioinformatic Tools
4.5. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Alaggio, R.; Amador, C.; Anagnostopoulos, I.; Attygalle, A.D.; de Oliveira Araujo, I.B.; Berti, E.; Bhagat, G.; Borges, A.M.; Boyer, D.; Calaminici, M.; et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022, 36, 1720–1748. [Google Scholar] [CrossRef] [PubMed]
- Available online: https://gco.iarc.fr/today/data/factsheets/cancers/34-Non-hodgkin-lymphoma-fact-sheet.pdf (accessed on 25 March 2023).
- International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s Lymphoma. N. Engl. J. Med. 1993, 329, 987–994. [Google Scholar] [CrossRef]
- Sehn, L.H.; Berry, B.; Chhanabhai, M.; Fitzgerald, C.; Gill, K.; Hoskins, P.; Klasa, R.; Savage, K.J.; Shenkier, T.; Sutherland, J.; et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007, 109, 1857–1861. [Google Scholar] [CrossRef] [PubMed]
- Kitajima, K.; Okada, M.; Yoshihara, K.; Tokugawa, T.; Sawada, A.; Yoshihara, S.; Tamaki, H.; Fujimori, Y.; Ueda, S.; Kawamoto, H.; et al. Predictive value of interim FDG-PET/CT findings in patients with diffuse large B-cell lymphoma treated with R-CHOP. Oncotarget 2019, 10, 5403–5411. [Google Scholar] [CrossRef] [PubMed]
- Rutherford, S.C.; Leonard, J.P. DLBCL cell of origin: What role should it plan in care today? Oncology 2018, 32, 445–449. [Google Scholar] [PubMed]
- Nguyen, L.; Papenhausen, P.; Shao, H. The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects. Genes 2017, 8, 116. [Google Scholar] [CrossRef]
- Shaffer, A.L.; Young, R.M.; Staudt, L.M. Pathogenesis of human B cell lymphomas. Annu. Rev. Immunol. 2012, 30, 565–610. [Google Scholar] [CrossRef] [PubMed]
- Schmitz, R.; Wright, G.W.; Huang, D.W.; Johnson, C.A.; Phelan, J.D.; Wang, J.Q.; Roulland, S.; Kasbekar, M.; Young, R.M.; Shaffer, A.L.; et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N. Engl. J. Med. 2018, 378, 1396–1407. [Google Scholar] [CrossRef]
- Chapuy, B.; Stewart, C.; Dunford, A.J.; Kim, J.; Kamburov, A.; Redd, R.A.; Lawrence, M.S.; Roemer, M.G.M.; Li, A.J.; Ziepert, M.; et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 2018, 24, 679–690. [Google Scholar] [CrossRef]
- Morin, R.D.; Arthur, S.E.; Hodson, D.J. Molecular profiling in diffuse large B-cell lymphoma: Why so many types of subtypes? Br. J. Hematol. 2022, 196, 814–829. [Google Scholar] [CrossRef]
- Younes, A.; Sehn, L.H.; Johnson, P.; Zinzani, P.L.; Hong, X.; Zhu, J.; Patti, C.; Belada, D.; Samoilova, O.; Suh, C.; et al. A randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. 2019, 37, 1285–1295. [Google Scholar] [PubMed]
- Nowakowski, G.S.; Chiappella, A.; Gascoyne, R.D.; Scott, D.W.; Zhang, Q.; Jurczak, W.; Özcan, M.; Hong, X.; Zhu, J.; Jin, J.; et al. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo plus R-CHOP in Previously Untreated Patients with ABC-Type Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. 2021, 39, 1317–1328. [Google Scholar] [PubMed]
- Tilly, H.; Morschhauser, F.; Sehn, L.H.; Friedberg, J.W.; Trněný, M.; Sharman, J.P.; Herbaux, C.; Burke, J.M.; Matasar, M.; Rai, S.; et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2022, 386, 351–363. [Google Scholar] [CrossRef]
- Wang, X.; Hong, Y.; Meng, S.; Gong, W.; Ren, T.; Zhang, T.; Liu, X.; Li, L.; Qiu, L.; Qian, Z.; et al. A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma. Clin. Immunol. 2022, 243, 109105. [Google Scholar] [PubMed]
- Mamgain, G.; Naithani, M.; Patra, P.; Mamgain, M.; Morang, S.; Nayak, J.; Kumar, K.; Singh, S.; Bakliwal, A.; Rajoreya, A.; et al. Next-Generation Sequencing Highlights of Diffuse Large B-cell Lymphoma in a Tertiary Care Hospital in North India. Cureus 2022, 14, e28241. [Google Scholar] [CrossRef] [PubMed]
- Cao, Y.; Zhu, T.; Zhang, P.; Xiao, M.; Yi, S.; Yang, Y.; Li, Q.; Ling, S.G.; Wang, Y.; Gao, L.Z.; et al. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors. Oncotarget 2016, 7, 83294–83307. [Google Scholar] [CrossRef]
- Gebauer, N.; Künstner, A.; Ketzer, J.; Witte, H.M.; Rausch, T.; Benes, V.; Zimmermann, J.; Gebauer, J.; Merz, H.; Bernard, V.; et al. Genomic insights into the pathogenesis of Epstein-Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing. Blood Cancer J. 2021, 26, 102. [Google Scholar] [CrossRef]
- Aldana, J.; Gardner, M.; Freitas, M.A. Integrative Multi-Omics Analysis of Oncogenic EZH2 Mutants: From Epigenetic Reprogramming to Molecular Signatures. Int. J. Mol. Sci. 2023, 24, 11378. [Google Scholar] [CrossRef]
- Oñate-Ocaña, L.F.; Ponce-Martínez, M.; Taja-Chayeb, L.; Gutiérrez-Hernández, O.; Avilés-Salas, A.; Cantú-de-León, D.; Dueñas-González, A.; Candelaria-Hernández, M. A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma. Rev. Investig. Clin. 2021, 73, 362–370. [Google Scholar] [CrossRef]
- Díaz, J.; Gutiérrez, O.; Taja, L.; Gutiérrez, S.; Avilés, A.; Candelaria, M. ctDNA is Useful to Detect Mutations at Codon 641 of Exon 16 of EZH2, a Biomarker for Relapse in Patients with Diffuse Large B-Cell Lymphoma. Cancers 2022, 14, 4650. [Google Scholar] [CrossRef]
- Özcalimli, A.; Erdogdu, I.H.; Turgutkaya, A.; Yavasoglu, I.; Döger, F.K.; Bolaman, A.Z. The evaluation of gene mutation profiles by next-generation sequencing in diffuse large B-cell lymphoma. Int. J. Lab. Hematol. 2023, 45, 310–316. [Google Scholar] [CrossRef] [PubMed]
- Pavlov, K.H.; Tadić, V.; Palković, P.B.; Sasi, B.; Magdić, N.; Petranović, M.Z.; Klasić, M.; Hančić, S.; Gršković, P.; Matulić, M.; et al. Different expression on DNMT1, PCNA, MCM2, CDT1, EZH2, GMNN and EP300 genes in lymphomagenesis of low vs high grade lymphoma. Pathol. Res. Pract. 2022, 239, 154170. [Google Scholar] [CrossRef] [PubMed]
- Chung, C. A promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma? Blood Lymphat. Cancer 2022, 12, 99–106. [Google Scholar] [CrossRef]
- Li, Z.; Duan, Y.; Ke, Q.; Wang, M.; Cen, H.; Zhu, X. Gene set-based identification of two immune subtypes of diffuse large B cell lymphoma for guiding immune checkpoint blocking therapy. Front. Genet. 2022, 13, 1000460. [Google Scholar] [CrossRef]
- Li, X.; Deng, M.; Zhang, C.; Luo, L.; Qian, H. Establishment of a primary renal lymphoma model and its clinical relevance. Front. Oncol. 2023, 13, 1089187. [Google Scholar] [CrossRef]
- Agostinelli, C.; Morandi, L.; Righi, S.; Cirillo, L.; Iommi, M.; Tonon, C.; Mazzatenta, D.; Zoli, M.; Rossi, M.; Bagnato, G.; et al. Genomic Profiling of Primary Diffuse Large B-cell Lymphoma of the Central Nervous System Suggest Novel Potential Therapeutic Targets. Mod. Pathol. 2023, 36, 100323. [Google Scholar] [CrossRef]
- Geng, H.; Jia, S.; Zhang, Y.; Li, J.; Yang, Q.; Zeng, L.; Zong, X.; Lu, Y.; Lu, S.; Zhou, J. Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement. Front. Immunol. 2023, 14, 1219167. [Google Scholar]
- Ebid, O.A.; ElArab, L.R.; Saad, A.R.; El Din, M.E.; Mostafa, N.; Swellam, M. Prognostic Impact of MYD88 and TP53 mutations in diffuse large B-cell Lymphoma. Ann. Hematol. 2023, 102, 3744–3788. [Google Scholar] [CrossRef]
- Elbaz, O.; Shaat, R.M.; El Ghaffar, H.A.A.; Shamaa, S.; Abdel-Masseih, H.M.; Anber, N.; Mortada, M.I. The Prevalence of MYD88 L265P and TNFAIP3 mutations and Their Correlation with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B-Cell Lymphoma. Asian Pac. J. Cancer Prev. 2023, 24, 2485–2491. [Google Scholar] [CrossRef]
- Mandato, E.; Yan, Q.; Ouyang, J.; Paczkowska, J.; Qin, Y.; Hao, Y.; Bojarczuk, K.; Hansen, J.; Chapuy, B.; Rodig, S.J.; et al. MYD88L256P augments proximal B-cell receptor signaling in large B-cell lymphoma via an interaction with DOCK8. Blood 2023, 142, 1219–1232. [Google Scholar] [CrossRef]
- Zhang, L.-B.; Zhang, L.; Xin, H.-L.; Wang, Y.; Bao, H.-Y.; Meng, Q.-Q.; Jiang, S.-Y.; Han, X.; Chen, W.-R.; Wang, J.-N.; et al. Coexistence of diffuse large B-cell lymphoma, acute myeloid leukemia and untreated lymphoplasmacytic lymphoma/waldenström macroglobulinemia in a same patient: A case report. World J. Clin. Cases 2023, 11, 4295–4305. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Shi, Z.Y.; Shi, Q.; Wang, S.; Zhang, M.C.; Shen, R.; He, Y.; Qiu, H.L.; Yi, H.M.; Dong, L.; et al. Clinicopathologic characteristics and prognostic analysis of testicular diffuse large B-cell lymphoma. Zonghua Xue Ye Xue Za Zhi 2023, 44, 321–327. [Google Scholar]
- Lee, Y.-P.; Yoon, S.E.; Cho, J.; Ko, Y.H.; Oh, D.; Ahn, Y.C.; Kim, W.S.; Kim, S.J. Real-World Data Analysis of Survival Outcomes and Central Nervous System Relapses in Testicular Diffuse Large B-cell lymphoma. Cancer Manag. Res. 2023, 15, 463–474. [Google Scholar] [CrossRef] [PubMed]
- Turi, M.; Sithara, A.A.; Hofmanová, L.; Žihala, D.; Radhakrishnan, D.; Vdovin, A.; Knápková, S.; Ševčíková, T.; Chyra, Z.; Jelínek, T.; et al. Transcriptome Analysis of Diffuse Large B-cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ and BATF as Downstream Targets of Oncogenic NF-kB Signaling. Int. J. Mol. Sci. 2023, 24, 5623. [Google Scholar] [CrossRef]
- Koh, H.; Eun, S.; Kim, S.; Kim, W.; Cho, J. Differences in mutational signature of diffuse large B-cell lymphomas according to the primary organ. Cancer Med. 2023, 12, 19732–19743. [Google Scholar] [CrossRef]
- Skoulidis, F.; Heymach, J. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat. Rev. Cancer 2019, 19, 495–509. [Google Scholar] [CrossRef]
- Steinhardt, J.J.; Gartenhaus, R.B. Promising personalized Therapeutic Options for Diffuse Large B-cell Lymphoma subtypes with Oncogene Addictions. Clin. Cancer Res. 2012, 18, 4538–4548. [Google Scholar] [CrossRef]
- Cheson, B.D.; Fisher, R.I.; Barrington, S.F.; Cavalli, F.; Schwartz, L.H.; Zucca, E.; Lister, T.A. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J. Clin. Oncol. 2014, 32, 3059–3068. [Google Scholar] [CrossRef]
- Oken, M.M.; Creech, R.H.; Tormey, D.C.; Horton, J.; Davis, T.E.; McFadden, E.T.; Carbone, P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982, 5, 649–655. [Google Scholar] [CrossRef]
- Hans, C.P.; Weisenburger, D.D.; Greiner, T.C.; Gascoyne, R.D.; Delabie, J.; Ott, G.; Mu, H.K.; Campo, E.; Braziel, R.M.; Jaffe, E.S.; et al. Confirmation of the molecular classification of diffuse lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103, 275–282. [Google Scholar] [CrossRef]
- Coiffier, B.; Thieblemont, C.; Van Den Neste, E.; Lepeu, G.; Plantier, I.; Castaigne, S.; Lefort, S.; Marit, G.; Macro, M.; Sebban, C.; et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 2010, 116, 2040–2045. [Google Scholar] [CrossRef]
- Meignan, M.; Gallamini, A.; Haioun, C.; Barrington, S.; Itti, E.; Luminari, S.; Polliack, A. Report on the 5th international workshop on positron emission tomography in lymphoma held in Menton. Leuk. Lymphoma 2015, 56, 1229–1232. [Google Scholar] [CrossRef]
- Landrum, M.J.; Lee, J.M.; Riley, G.R.; Jang, W.; Rubinstein, W.S.; Church, D.M.; Maglott, D.R. ClinVar: Public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014, 42, D980–D985. [Google Scholar] [CrossRef] [PubMed]
- Tate, J.G.; Bamford, S.; Jubb, H.C.; Sondka, Z.; Beare, D.M.; Bindal, N.; Boutselakis, H.; Cole, C.G.; Creatore, C.; Dawson, E.; et al. COSMIC: The Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2019, 47, D941–D948. [Google Scholar] [CrossRef]
- Adzhubei, I.; Jordan, D.M.; Sunyaev, S.R. Predicting functional effect of human missense mutations using PolyPhen-2. Curr. Protoc. Hum. Genet. 2013, 7, 1–41. [Google Scholar] [CrossRef]
- Vaser, R.; Adusumalli, S.; Leng, S.N.; Sikic, M.; Ng, P.C. SIFT missense predictions for genomes. Nat. Protoc. 2016, 11, 1–9. [Google Scholar] [CrossRef]
- Shihab, H.A.; Gough, J.; Mort, M.; Cooper, D.N.; Day, I.N.; Gaunt, T.R. Ranking non-synonymous single nucleotide polymorphisms based on disease concepts. Hum. Genomics 2014, 8, 11. [Google Scholar] [CrossRef]
- Lek, M.; Karczewski, K.J.; Minikel, E.V.; Samocha, K.E.; Banks, E.; Fennell, T.; O’Donnell-Luria, A.H.; Ware, J.S.; Hill, A.J.; Cummings, B.B.; et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 2016, 536, 285–291. [Google Scholar] [CrossRef]
- McLaren, W.; Gil, L.; Hunt, S.E.; Riat, H.S.; Ritchie, G.R.S.; Thormann, A.; Flicek, P.; Cunningham, F. The Ensembl Variant Effect Predictor. Genome Biol. 2016, 17, 122. [Google Scholar] [CrossRef]
- Tamborero, D.; Rubio-Perez, C.; Deu-Pons, J.; Schroeder, M.P.; Vivancos, A.; Rovira, A.; Tusquets, I.; Albanell, J.; Rodon, J.; Tabernero, J.; et al. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. Genome Med. 2018, 10, 25. [Google Scholar] [CrossRef]
- Muiños, F.; Martínez, F.; Pich, O.; Gonzalez, A.; Lopez, N. In silico saturation mutagenesis of cancer genes. Nature 2021, 596, 428–432. [Google Scholar] [CrossRef] [PubMed]
All Patients | Driver Mutations | ||||||
---|---|---|---|---|---|---|---|
None | Present | ||||||
Characteristic | N = 185 | % (100) | N = 75 | % (100) | N = 110 | % (100) | p |
Female/male | 93/92 | 50.3/49.7 | 37/38 | 49.3/50.7 | 56/54 | 50.9/49.1 | 0.44 |
ECOG:
| 128 43 12 2 | 69.2 23.2 6.5 1.1 | 58 13 4 0 | 77.4 17.3 5.3 - | 70 30 8 2 | 63.7 27.2 7.3 1.8 | 0.19 |
B symptoms
| 131 54 | 70.8 29.2 | 57 18 | 76.0 24.0 | 74 36 | 67.2 32.8 | 0.27 |
Bulky
| 102 83 | 55.1 44.9 | 45 30 | 60.0 40.0 | 56 54 | 51.0 49.0 | 0.33 |
Clinical stage:
| 18 33 21 113 | 9.7 17.8 11.4 61.1 | 9 19 7 40 | 12.0 25.3 9.3 53.4 | 9 14 14 73 | 8.1 12.8 12.8 66.3 | 0.09 |
Extranodal disease
| 66 67 20 32 | 36 37 11 16 | 30 24 10 11 | 40.0 32.0 13.4 14.6 | 39 43 10 18 | 35.4 39.2 9.1 16.3 | 0.44 |
IPI score *:
| 45 40 35 65 | 24.4 21.6 19 35 | 21 20 12 22 | 28.0 26.6 16.0 29.4 | 24 20 23 43 | 21.8 18.2 20.9 39.1 | 0.24 |
Cell of origin:
| 126 59 | 68.1 31.9 | 49 26 | 65.3 34.7 | 77 33 | 70.0 30.0 | 0.24 |
Response to treatment:
| 129 10 3 26 17 | 69.7 5.4 1.6 14.0 9.3 | 56 4 1 8 6 | 74.8 5.3 1.3 10.6 8.0 | 73 6 2 18 11 | 66.5 5.4 1.8 16.3 10.0 | 0.77 |
Median ± SD RFS (months) | 39.12 + 27.97 | 41.31 + 27.94 | 37.63 + 28.09 | 0.44 | |||
Median ± SD OS (months) | 41.99 + 26.47 | 42.52 + 27.17 | 41.63 + 26.09 | 0.83 |
Multivariate Analysis for OS | Multivariate Analysis for RFS | |||||
---|---|---|---|---|---|---|
HR | IC 95% | p-Value | HR | IC 95% | p-Value | |
Age | 1.04 | 1.01–1.06 | 0.002 | 1.02 | 0.91–1.06 | 0.26 |
ECOG | 1.50 | 0.99–2.28 | 0.021 | 1.32 | 0.96–1.98 | 0.055 |
Bulky mass | 1.33 | 0.70–2.53 | 0.568 | 1.34 | 0.71–2.52 | 0.449 |
Clinical stage | 1.47 | 0.99–2.16 | 0.061 | 1.44 | 0.97–2.13 | 0.066 |
IPI score | 0.88 | 0.60–1.28 | 0.702 | 0.94 | 0.65–1.37 | 0.635 |
ARID1A | 7.98 | 1.91–35.24 | 0.006 | 5.17 | 1.19–2.59 | |
Number of driver mutations | 0.33 | 0.13–0.83 | 0.016 | 0.34 | 0.13–1.12 | 0.086 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Candelaria, M.; Cerrato-Izaguirre, D.; Gutierrez, O.; Diaz-Chavez, J.; Aviles, A.; Dueñas-Gonzalez, A.; Malpica, L. Characterizing the Mutational Landscape of Diffuse Large B-Cell Lymphoma in a Prospective Cohort of Mexican Patients. Int. J. Mol. Sci. 2024, 25, 9328. https://doi.org/10.3390/ijms25179328
Candelaria M, Cerrato-Izaguirre D, Gutierrez O, Diaz-Chavez J, Aviles A, Dueñas-Gonzalez A, Malpica L. Characterizing the Mutational Landscape of Diffuse Large B-Cell Lymphoma in a Prospective Cohort of Mexican Patients. International Journal of Molecular Sciences. 2024; 25(17):9328. https://doi.org/10.3390/ijms25179328
Chicago/Turabian StyleCandelaria, Myrna, Dennis Cerrato-Izaguirre, Olga Gutierrez, Jose Diaz-Chavez, Alejandro Aviles, Alfonso Dueñas-Gonzalez, and Luis Malpica. 2024. "Characterizing the Mutational Landscape of Diffuse Large B-Cell Lymphoma in a Prospective Cohort of Mexican Patients" International Journal of Molecular Sciences 25, no. 17: 9328. https://doi.org/10.3390/ijms25179328